Zheng Yi-Zi, Li Jia-Ying, Ning Lv-Wen, Xie Ni
Department of Thyroid and Breast Surgery, Shenzhen Breast Tumor Research Center for Diagnosis and Treatment, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen University, Shenzhen, Guangdong, People's Republic of China.
Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China.
Breast Cancer (Dove Med Press). 2022 Dec 21;14:475-487. doi: 10.2147/BCTT.S387209. eCollection 2022.
Tripartite motif-containing protein (TRIM) family members play crucial roles in carcinogenesis and chemotherapy resistance. In this study, we aimed to determine whether TRIM58 protein expression is related to patient responses to neoadjuvant therapy (NAT) and their survival outcome.
Immunohistochemistry was performed on female breast cancer samples from biopsies before NAT in Shenzhen Second People's Hospital. Univariate and multivariate logistic regression tests were used to analyze the association between TRIM58 protein expression and pathological complete response (pCR). The Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with a 95% confidence interval (95% CI). The Kaplan-Meier plotter database was used to analyze the prognostic value of TRIM58.
High TRIM58 expression was associated with small tumor size in all the patients (n = 58). Multivariate analysis suggested that low TRIM58 expression was an independent predictive factor for higher pCR (odds ratio = 0.06, 95% CI 0.005-0.741, = 0.028). The Kaplan-Meier Plotter dataset suggested that the TRIM58 high-expression group showed a worse 5-year overall survival than the low-expression group (HR = 1.34, 95% CI 1.07-1.67, = 0.01). Pathway analysis revealed the potential mechanisms of TRIM58 in chemoresistance.
Our study suggests that TRIM58 is a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer. It may also help to identify candidate responders and determine treatment strategies.
含三联基序蛋白（TRIM）家族成员在肿瘤发生和化疗耐药中起关键作用。在本研究中，我们旨在确定TRIM58蛋白表达是否与患者对新辅助治疗（NAT）的反应及其生存结果相关。
对深圳市第二人民医院接受NAT前活检的女性乳腺癌样本进行免疫组织化学检测。采用单因素和多因素逻辑回归分析TRIM58蛋白表达与病理完全缓解（pCR）之间的关联。使用Cox比例风险模型计算调整后的风险比（HR）及95%置信区间（95%CI）。利用Kaplan-Meier Plotter数据库分析TRIM58的预后价值。
在所有患者（n = 58）中，TRIM58高表达与肿瘤体积小相关。多因素分析表明，TRIM58低表达是pCR较高的独立预测因素（比值比 = 0.06，95%CI 0.005 - 0.741，P = 0.028）。Kaplan-Meier Plotter数据集表明，TRIM58高表达组的5年总生存率低于低表达组（HR = 1.34，95%CI 1.07 - 1.67，P = 0.01）。通路分析揭示了TRIM58在化疗耐药中的潜在机制。
我们的研究表明，TRIM58是乳腺癌新辅助化疗敏感性和长期临床结局的一个有前景的生物标志物。它还可能有助于识别潜在的反应者并确定治疗策略。
